检索结果-南通市图书馆

Recent trends in bone metastasis treatments:A historical comparison using the new Katagiri score system

World Journal of Clinical Cases 2024年第15期12卷 2499-2505页

作者： Kenji Matsuda Kazuhiro Shimazu Hanae Shinozaki Koji Fukuda Taichi Yoshida Daiki Taguchi Kyoko Nomura Hiroyuki Shibata Department of Clinical Oncology Akita University Graduate School of MedicineAkita 010-8543Japan Department of Environmental Health Science and Public Health Akita University Graduate School of MedicineAkita 010-8543Japan Department of Comprehensive Cancer Control Akita University Graduate School of MedicineAkita 010-8543Japan

BACKGROUND Bone metastasis has various negative *** of daily living(ADL)and quality of life(QOL)can be significantly decreased,survival may be impacted,and medical expenses may *** is estimated that at least 5%cancer patients might be suffering from bone *** 2016,we published the Comprehensive Guidelines for the Diagnosis and Treatment of Bone *** then,the therapeutic outcomes for patients have gradually *** life expectancy is a major determinant of surgical intervention,the strategy should be modified if the prolongation of survival is to be *** To monitor how bone metastasis treatment has changed before and after launch of our guidelines for bone *** For advanced cancer patients with bone metastasis who visited the Department of Clinical Oncology at Akita University hospital between 2012 and 2023,parameters including the site and number of bone metastases,laboratory data,and survival time,were extracted from electronic medical records and the Katagiri score was *** association with survival was determined for each *** Data from 136 patients were *** 1-year survival rate for the poor prognosis group with a higher Katagiri score was 20.0%in this study,which was 6%and an apparent improvement from 2014 when the scoring system was *** factors significantly affecting survival included five or more bone metastases than less(P=0.0080),and treatment with chemotherapy(Pimmune checkpoint inhibitors(P=0.0128).In recent years,advances in various treatment methods have extended the survival period for patients with advanced *** is necessary not only to simply extend survival time,but also to maintain ADL and improve *** Various therapeutic interventions including surgical approach for bone metastasis,which is a disorder of locomotor organs,are increasingly *** and scoring system for p

关键词： Bone metastasis New Katagiri scoring system Prognosis immune check point inhibitors Survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Tumor immunotherapy in the treatment of NSCLC

Tumor immunotherapy in the treatment of NSCLC

引用

第十二届全国免疫学学术大会

作者： SUN Xiaoying ZHENG Yuanqiang CUI Zhengrong SHI Yanchun Inner Mongolia Key Laboratory of Molecular Biology Inner Mongolia Medical University Pharmaceutics Division College of Pharmacythe University of Texas at Austin

Lung cancer is the leading cause of cancer mortality worldwide,accounting for 1.3 million deaths each ***-small cell lung cancer(NSCLC) accounts for approximately 80-85%of all lung cancers and is usually diagnosed at an advanced stage with poor *** chemoradiotherapy improves overall survival as compared to sequential chemotherapy and radiation therapy,but is associated with higher rates of *** has shown promising results in various types of ***,immune-checkpoint inhibitor(ICPI) drugs,which include antibodies against Cytotoxic T-Lymphocyte Antigen-4(CTLA-4),programmed cell death protein 1(PD-1) and programmed cell death protein ligand 1(PD-L1),have been shown to induce durable complete responses in a proportion of patients with particular efficacy demonstrated in both the first line and refractory setting in advanced *** inhibitors are the most striking innovation in the clinical development of immunotherapy.T-cell checkpoint inhibitors that target the PD-1 and PD-L1 are changing the current strategy in the treatment of advanced NSCLC without driver gene mutations such as anti-PD-1/PD-L1,pembrolizumab,are a novel class of inhibitors that function as a tumor suppressing factor via modulation of immune cell-tumor cell interaction.

关键词： NSCLC Tumor immunotherapy immune check point inhibitors PD-1/PD-L1

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：